TherapeuticsMD’s (TXMD) “Buy” Rating Reiterated at Noble Financial

Noble Financial reiterated their buy rating on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Friday morning.

Several other research firms have also recently weighed in on TXMD. BidaskClub upgraded shares of TherapeuticsMD from a strong sell rating to a sell rating in a research report on Wednesday, October 25th. Jefferies Group restated a buy rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research report on Friday, September 8th. Cantor Fitzgerald restated a buy rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research report on Monday, September 4th. Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the company a buy rating in a research report on Monday, October 16th. Finally, Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the company a buy rating in a research report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $14.50.

Shares of TherapeuticsMD (TXMD) opened at $6.04 on Friday. The firm has a market cap of $1,280.00, a PE ratio of -15.49 and a beta of 1.06. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company’s quarterly revenue was down 19.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) EPS. equities research analysts forecast that TherapeuticsMD will post -0.37 earnings per share for the current year.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction dated Friday, December 8th. The stock was bought at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now directly owns 3,555 shares in the company, valued at $22,076.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 23.92% of the stock is owned by insiders.

Several large investors have recently modified their holdings of TXMD. Schwab Charles Investment Management Inc. grew its position in shares of TherapeuticsMD by 10.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after buying an additional 67,855 shares during the period. Rhumbline Advisers grew its position in shares of TherapeuticsMD by 3.5% during the 2nd quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after buying an additional 6,232 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of TherapeuticsMD during the 2nd quarter worth approximately $596,000. SG Americas Securities LLC acquired a new stake in shares of TherapeuticsMD during the 2nd quarter worth approximately $554,000. Finally, Legal & General Group Plc grew its position in shares of TherapeuticsMD by 6.5% during the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after buying an additional 3,441 shares during the period. Institutional investors own 73.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/01/02/therapeuticsmds-txmd-buy-rating-reiterated-at-noble-financial.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply